TSHA Q3 2023 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M

Gross Profit

$4M93.0% margin

Operating Income

-$16M-329.4% margin

Net Income

-$117M-2467.1% margin

EPS (Diluted)

$-0.93

QoQ Revenue Growth

+98.2%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$196M

Total Liabilities

$245M

Stockholders' Equity

-$49M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$16M	-$25M	+38.6%
Net Income	-$117M	-$27M	-341.4%